TriangleFOR PATIENTS · SOURCE READING
Systemic immunotherapy
Source: Bladder Cancer Treatment, National Cancer Institute.
Source updated: September 12, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
Context: Immunotherapy
Systemic immunotherapy drugs used to treat urothelial cancer (a type of bladder cancer) include:
atezolizumab
Source links and citations
avelumab
Source links and citations
nivolumab
Source links and citations
pembrolizumab
Source links and citations
These drugs work in more than one way to kill cancer cells. They are also considered targeted therapy because they target specific changes or substances in cancer cells (visit the section on Targeted therapy).
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice